Baojin Hua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Baojin Hua has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Honggang Zheng
Department of Oncology, Guang'anmen Hospital China Academy of Chinese Medical Sciences Beijing China
15 shared publicationsXing Zhang
Department of Oncology, Academy of Chinese Medical Sciences, Guang’anmen Hospital, China , Beijing, China
14 shared publicationsJuling Jiang
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
12 shared publicationsRui Liu
Department of Oncology, Academy of Chinese Medical Sciences, Guang’anmen Hospital, China , Beijing, China
11 shared publicationsQiujun Guo
Department of Oncology, Guang'anmen Hospital China Academy of Chinese Medical Sciences Beijing China
10 shared publicationsShuntai Chen
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Bejing, China
10 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 245
An intracranial small cell lung cancer inoculation model in BALB/c-nu mice reveals tumor-associated neuroinflammation and synaptic injury
- 3 September 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 245
Open AccessAn intracranial small cell lung cancer inoculation model in BALB/c-nu mice reveals tumor-associated neuroinflammation and synaptic injury
- Open Access
- 20 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2195
Cancer-Related Psychological Distress over the Past Decade: A Bibliometric Analysis of Research Trends, Hotspots, and Emerging Areas
Background: Cancer-related psychological distress is a major concern in comprehensive oncology care because it substantially impairs patients’ quality of life and may adversely affect treatment adherence, outcomes, and prognosis. Over the past decade, research in this field has expanded rapidly; however, the overall knowledge structure, global research patterns, major contributors, and emerging hotspots remain insufficiently characterized. A bibliometric analysis is therefore needed to systematically map the development of cancer-related psychological distress research and identify evolving directions for future investigation. Methods: Publications related to cancer-related psychological distress published between 1 January 2015 and 31 December 2024 were retrieved from the Web of Science Core Collection and Scopus databases. The database searches were conducted on 10 March 2025. Bibliometric analyses were performed using VOSviewer (version 1.6.20), CiteSpace (version 6.3.R1), and the R package bibliometrix (version 5.3). Publication trends, country and institutional contributions, journal distribution, author collaboration networks, co-cited references, keyword co-occurrence, burst keywords, and thematic evolution were analyzed. Results: A total of 7063 publications were included in the bibliometric analysis, including 6162 articles and 901 reviews. Annual publication output increased from 465 publications in 2015 to 924 publications in 2024. The main contributing countries were the United States, Australia, China, Germany, and the United Kingdom. The United States ranked first in publication volume and total citations. Psycho-Oncology and Supportive Care in Cancer were the leading journals by publication volume and total citations. Major research themes included quality of life, psychological distress, depression, anxiety, breast cancer, distress screening, survivorship, and palliative care. Seven high-frequency keywords—“cancer,” “quality of life,” “psychological distress,” “depression,” “anxiety,” “breast cancer,” and “distress”—each appeared more than 500 times, representing the core research topics. Emerging keywords such as “informal caregivers,” “young adults,” “guidelines,” and “adult survivors” reflected increasing attention to caregiver support, age-specific psychosocial needs, survivorship care, and standardized clinical management. Conclusions: This bibliometric analysis provides a comprehensive overview of global research on cancer-related psychological distress from 2015 to 2024. The findings reveal publication trends, major contributors, collaboration patterns, core research themes, knowledge structures, and emerging topics in this field. Current research has gradually shifted from general descriptions of psychological distress toward survivorship care, caregiver support, standardized screening, and guideline-based management. Future studies should strengthen interdisciplinary collaboration, improve standardized assessment and screening approaches, and further explore emerging areas such as caregiver support, young adult cancer populations, survivorship care, and digital health and artificial intelligence-assisted approaches, which require further validation before routine clinical implementation.
- 20 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2195
Open AccessCancer-Related Psychological Distress over the Past Decade: A Bibliometric Analysis of Research Trends, Hotspots, and Emerging Areas
Background: Cancer-related psychological distress is a major concern in comprehensive oncology care because it substantially impairs patients’ quality of life and may adversely affect treatment adherence, outcomes, and prognosis. Over the past decade, research in this field has expanded rapidly; however, the overall knowledge structure, global research patterns, major contributors, and emerging hotspots remain insufficiently characterized. A bibliometric analysis is therefore needed to systematically map the development of cancer-related psychological distress research and identify evolving directions for future investigation. Methods: Publications related to cancer-related psychological distress published between 1 January 2015 and 31 December 2024 were retrieved from the Web of Science Core Collection and Scopus databases. The database searches were conducted on 10 March 2025. Bibliometric analyses were performed using VOSviewer (version 1.6.20), CiteSpace (version 6.3.R1), and the R package bibliometrix (version 5.3). Publication trends, country and institutional contributions, journal distribution, author collaboration networks, co-cited references, keyword co-occurrence, burst keywords, and thematic evolution were analyzed. Results: A total of 7063 publications were included in the bibliometric analysis, including 6162 articles and 901 reviews. Annual publication output increased from 465 publications in 2015 to 924 publications in 2024. The main contributing countries were the United States, Australia, China, Germany, and the United Kingdom. The United States ranked first in publication volume and total citations. Psycho-Oncology and Supportive Care in Cancer were the leading journals by publication volume and total citations. Major research themes included quality of life, psychological distress, depression, anxiety, breast cancer, distress screening, survivorship, and palliative care. Seven high-frequency keywords—“cancer,” “quality of life,” “psychological distress,” “depression,” “anxiety,” “breast cancer,” and “distress”—each appeared more than 500 times, representing the core research topics. Emerging keywords such as “informal caregivers,” “young adults,” “guidelines,” and “adult survivors” reflected increasing attention to caregiver support, age-specific psychosocial needs, survivorship care, and standardized clinical management. Conclusions: This bibliometric analysis provides a comprehensive overview of global research on cancer-related psychological distress from 2015 to 2024. The findings reveal publication trends, major contributors, collaboration patterns, core research themes, knowledge structures, and emerging topics in this field. Current research has gradually shifted from general descriptions of psychological distress toward survivorship care, caregiver support, standardized screening, and guideline-based management. Future studies should strengthen interdisciplinary collaboration, improve standardized assessment and screening approaches, and further explore emerging areas such as caregiver support, young adult cancer populations, survivorship care, and digital health and artificial intelligence-assisted approaches, which require further validation before routine clinical implementation.
- Open Access
- 6 May 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 126
Shuangshen granules enhance anti-PD1 therapy effectiveness in lung adenocarcinoma by modulating myeloid-derived suppressor cell-induced T cell exhaustion
Background: Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. A traditional Chinese medicine (TCM) formula of Shuangshen granules (SSG) has demonstrated potential in alleviating cancer side effects and improving survival rate. Despite clinical evidence supporting its benefit, there is still insufficient understanding of the active compounds in SSG and their underlying mechanisms, which limits its broader clinical application. Methods: Lewis lung carcinoma (LLC) tumor-bearing mouse model was established to assess the efficacy of combined SSG and anti-PD-1 therapy in vivo, and myeloid-derived suppressor cells (MDSC) and CD8 + T cells were isolated for in vitro co-culture experiments, while pathological examination was conducted using hematoxylin and eosin (HE). The expression of PD-1, TIM-3, CTLA-4, LAG-3, Arg-1, IDO, iNOS, PD-L1 and Gal-9 was detected using immunohistochemistry (IHC), immunofluorescence, and flow cytometry and Western blotting. The expression of IL-2, TNF-α and IFN-γ were detected by reverse transcription-quantitative polymerase chain reaction (qPCR). Concentrations of IL-10 and TGF-β were measured by enzyme-linked immunosorbent assay (ELISA). Network pharmacology and molecular docking were utilized to screen for potential therapeutic targets and intervening signaling pathways of SSG in lung adenocarcinoma (LUAD). The predictions derived from this approach were further verified using Western blotting. Results: In vivo experiments using LLC xenograft mice demonstrated that SSG suppressed tumor growth in a dose-dependent manner, with high-dose SSG showing optimal efficacy in inhibiting tumor angiogenesis and cell proliferation. SSG enhances anti-tumor immunity by reducing T cell exhaustion and MDSC-mediated immunosuppression, with SSG + anti-PD-1 combination therapy synergistically optimizing the tumor immune microenvironment. Network pharmacology analysis revealed 5 hub targets (IL2, STAT3, HSP90AA1, LGALS3, and FGF2) associated with immune, LUAD, and active ingredients of SSG, with significant enrichment in the PI3K-Akt pathway. Compared with the control group, the protein expression levels of p-PI3K and p-Akt in the SSG group were significantly down-regulated, indicating that the PI3K-Akt pathway may be inhibited. Conclusions: SSG could dose-dependently inhibit LLC tumor growth in mice and exert antitumor effects by alleviating T-cell exhaustion and MDSC-mediated immunosuppression. Notably, IL2, STAT3, HSP90AA1, LGALS3 and FGF2, as potential targets of SSG, were significantly enriched in the PI3K-Akt pathway, which provide a novel perspective for the treatment of LUAD.
- 6 May 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 126
Open AccessShuangshen granules enhance anti-PD1 therapy effectiveness in lung adenocarcinoma by modulating myeloid-derived suppressor cell-induced T cell exhaustion
Background: Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. A traditional Chinese medicine (TCM) formula of Shuangshen granules (SSG) has demonstrated potential in alleviating cancer side effects and improving survival rate. Despite clinical evidence supporting its benefit, there is still insufficient understanding of the active compounds in SSG and their underlying mechanisms, which limits its broader clinical application. Methods: Lewis lung carcinoma (LLC) tumor-bearing mouse model was established to assess the efficacy of combined SSG and anti-PD-1 therapy in vivo, and myeloid-derived suppressor cells (MDSC) and CD8 + T cells were isolated for in vitro co-culture experiments, while pathological examination was conducted using hematoxylin and eosin (HE). The expression of PD-1, TIM-3, CTLA-4, LAG-3, Arg-1, IDO, iNOS, PD-L1 and Gal-9 was detected using immunohistochemistry (IHC), immunofluorescence, and flow cytometry and Western blotting. The expression of IL-2, TNF-α and IFN-γ were detected by reverse transcription-quantitative polymerase chain reaction (qPCR). Concentrations of IL-10 and TGF-β were measured by enzyme-linked immunosorbent assay (ELISA). Network pharmacology and molecular docking were utilized to screen for potential therapeutic targets and intervening signaling pathways of SSG in lung adenocarcinoma (LUAD). The predictions derived from this approach were further verified using Western blotting. Results: In vivo experiments using LLC xenograft mice demonstrated that SSG suppressed tumor growth in a dose-dependent manner, with high-dose SSG showing optimal efficacy in inhibiting tumor angiogenesis and cell proliferation. SSG enhances anti-tumor immunity by reducing T cell exhaustion and MDSC-mediated immunosuppression, with SSG + anti-PD-1 combination therapy synergistically optimizing the tumor immune microenvironment. Network pharmacology analysis revealed 5 hub targets (IL2, STAT3, HSP90AA1, LGALS3, and FGF2) associated with immune, LUAD, and active ingredients of SSG, with significant enrichment in the PI3K-Akt pathway. Compared with the control group, the protein expression levels of p-PI3K and p-Akt in the SSG group were significantly down-regulated, indicating that the PI3K-Akt pathway may be inhibited. Conclusions: SSG could dose-dependently inhibit LLC tumor growth in mice and exert antitumor effects by alleviating T-cell exhaustion and MDSC-mediated immunosuppression. Notably, IL2, STAT3, HSP90AA1, LGALS3 and FGF2, as potential targets of SSG, were significantly enriched in the PI3K-Akt pathway, which provide a novel perspective for the treatment of LUAD.
- 15 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105335
Mapping the immune microenvironment of non-small cell lung cancer
- 15 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 223, 105335
Mapping the immune microenvironment of non-small cell lung cancer
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 5626229
Shuangshen Granule Regulates Tumor Cell Exosomes Through MIF‐miR‐34a‐KLF4 Pathway and Affects Macrophage Polarization Against Lung Cancer
The incidence and mortality of lung cancer are among the highest in the world, involving a variety of complex pathological mechanisms and processes. Previous studies have demonstrated that the tumor immunosuppressive microenvironment (TIME) plays a key role in tumor progression, promoting tumor invasion and metastasis and leading to resistance to therapy. Tumor‐associated macrophages (TAMs) are important cell components in TIME, and their phenotypes affect the prognosis of tumors. Tumor‐derived exosomes carrying specific information as a medium of crosstalk between macrophages and tumor cells are considered to be an underexplored information transfer medium affecting tumor progression and tumor microenvironment remodeling. In the previous study, we found that Shuangshen granule (SSG) can reduce the formation of lung tumors in mouse models of spontaneous lung cancer, but the specific mechanism of SSG inhibiting lung cancer has not been solved. Starting from the exosomes of tumor cells, we established the M1‐like TAMs overexpression mouse lung cancer transplantation tumor model and constructed MIF +/+ Lewis stable transfection cell line and shMIF Lewis stable transfection cell line to analyze the specific molecular biological mechanism of SSG inhibiting lung cancer. The experimental results showed that SSG significantly reduced the volume and mass of Lewis lung cancer xenografts in mice, and its inhibitory effect on Lewis lung cancer was related to the increase in the proportion of M1‐like TAMs. Flow cytometry and western blot revealed that SSG can increase the proportion of CD8 + central memory T cells, reduce the proportion of CD8 + effector memory T cells, reduce the proportion of CD4 + CD25 + Foxp3 + Treg cells, and play a role in regulating the tumor microenvironment. In vitro experiments further showed that SSG drug–containing serum could inhibit the expression of MIF protein and RNA in MIF +/+ Lewis cells and increase the expression of miR‐34a in MIF +/+ Lewis cell exosomes. Interestingly, we also found that MIF +/+ Lewis cell–derived exosomes after SSG‐containing serum intervention can reverse the increase in the proportion of M2‐like TAMs and increase the proportion of M1‐like TAMs. Subsequent gene modification experiments showed that MIF +/+ Lewis cell exosomes can increase the expression of the KLF4 gene in macrophages in vitro. In conclusion, our study revealed that SSG can regulate the polarization of TAMs through lung cancer cell–derived exosomes, and its mechanism is related to the MIF‐miR‐34a‐KLF4 pathway. Summary: SSG can inhibit the proliferation of lung cancer, which is related to the antitumor mechanism involving macrophages. The poor prognosis of lung cancer caused by macrophage migration inhibitory factor (MIF) is related to the TAM phenotype, and SSG can inhibit lung cancer by inhibiting MIF. SSG regulates the tumor cell MIF‐MiR‐34a exosome pathway and regulates the polarization and function of TAMs.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 5626229
Open AccessShuangshen Granule Regulates Tumor Cell Exosomes Through MIF‐miR‐34a‐KLF4 Pathway and Affects Macrophage Polarization Against Lung Cancer
The incidence and mortality of lung cancer are among the highest in the world, involving a variety of complex pathological mechanisms and processes. Previous studies have demonstrated that the tumor immunosuppressive microenvironment (TIME) plays a key role in tumor progression, promoting tumor invasion and metastasis and leading to resistance to therapy. Tumor‐associated macrophages (TAMs) are important cell components in TIME, and their phenotypes affect the prognosis of tumors. Tumor‐derived exosomes carrying specific information as a medium of crosstalk between macrophages and tumor cells are considered to be an underexplored information transfer medium affecting tumor progression and tumor microenvironment remodeling. In the previous study, we found that Shuangshen granule (SSG) can reduce the formation of lung tumors in mouse models of spontaneous lung cancer, but the specific mechanism of SSG inhibiting lung cancer has not been solved. Starting from the exosomes of tumor cells, we established the M1‐like TAMs overexpression mouse lung cancer transplantation tumor model and constructed MIF +/+ Lewis stable transfection cell line and shMIF Lewis stable transfection cell line to analyze the specific molecular biological mechanism of SSG inhibiting lung cancer. The experimental results showed that SSG significantly reduced the volume and mass of Lewis lung cancer xenografts in mice, and its inhibitory effect on Lewis lung cancer was related to the increase in the proportion of M1‐like TAMs. Flow cytometry and western blot revealed that SSG can increase the proportion of CD8 + central memory T cells, reduce the proportion of CD8 + effector memory T cells, reduce the proportion of CD4 + CD25 + Foxp3 + Treg cells, and play a role in regulating the tumor microenvironment. In vitro experiments further showed that SSG drug–containing serum could inhibit the expression of MIF protein and RNA in MIF +/+ Lewis cells and increase the expression of miR‐34a in MIF +/+ Lewis cell exosomes. Interestingly, we also found that MIF +/+ Lewis cell–derived exosomes after SSG‐containing serum intervention can reverse the increase in the proportion of M2‐like TAMs and increase the proportion of M1‐like TAMs. Subsequent gene modification experiments showed that MIF +/+ Lewis cell exosomes can increase the expression of the KLF4 gene in macrophages in vitro. In conclusion, our study revealed that SSG can regulate the polarization of TAMs through lung cancer cell–derived exosomes, and its mechanism is related to the MIF‐miR‐34a‐KLF4 pathway. Summary: SSG can inhibit the proliferation of lung cancer, which is related to the antitumor mechanism involving macrophages. The poor prognosis of lung cancer caused by macrophage migration inhibitory factor (MIF) is related to the TAM phenotype, and SSG can inhibit lung cancer by inhibiting MIF. SSG regulates the tumor cell MIF‐MiR‐34a exosome pathway and regulates the polarization and function of TAMs.
- Open Access
- 19 December 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 194, 118927
Mitochondria-targeted nanosystem-mediated delivery of cryptotanshinone for enhanced suppression of non-small cell lung cancer
- 19 December 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 194, 118927
Open AccessMitochondria-targeted nanosystem-mediated delivery of cryptotanshinone for enhanced suppression of non-small cell lung cancer
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Bidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Open AccessBidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- Open Access
- 4 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1553-1579
Worldwide research on 3D printing for cancer: a dual-method analysis of bibliometrics and stratified focused thematic
Aim: This study investigates the application of three-dimensional (3D) printing in cancer research and treatment, highlighting the current advancements, key areas of interest, and emerging trends in the field. Methods: Literature records and cited references were retrieved from the Web of Science Core Collection (WOSCC) database and analyzed using Excel 2019, Bibliometrix, VOSviewer, and CiteSpace. Based on the scientometric results, a stratified and focused thematic analysis was performed by cancer type to enhance clinical relevance and investigate tumor-specific applications. Results: A total of 2312 publications on 3D printing in cancer were identified, with the earliest published in 2006. Publications originated from 2740 institutions across 82 countries, with China leading the field with 779 articles. Sichuan University was the most prolific institution, publishing 75 articles. Frontiers in Oncology had the highest number of publications with 49 publications, while Biomaterials was the most frequently cited journal with 3354 citations. Contributions to the field have been made by 13 066 contributing authors, with Tu Chongqi having 39 publications being the most productive. Key research areas focus on utilizing 3D printing for preoperative planning and patient education in tumor surgery, treating malignant bone tumors, advancing tumor radiotherapy, constructing in vitro tumor cell models, and expanding 3D bioprinting applications in cancer therapy. Future directions may include developments in limb-salvage and prosthetic reconstruction, the use of 3D bioprinting tumor microenvironment (TME) models to investigate antitumor mechanisms, and applications of 3D printing in cancer drug resistance. Among the most frequently studied tumor types, research on malignant bone tumors has primarily focused on reconstruction and tissue regeneration. In breast cancer, key areas include surgical planning, radiotherapy bolus design, tumor microenvironment modeling, and drug delivery. Lung cancer studies have emphasized surgical simulation, imaging phantoms, and bioprinted tumor models, while cervical cancer research has concentrated on customized brachytherapy applicators and preclinical bioprinting platforms. Additional insights on liver, prostate, head and neck, colorectal cancers, and glioblastoma are provided in the supplementary tables to support targeted research efforts. Conclusions: This study provides a comprehensive overview of the global applications of 3D printing in cancer research from 2000 to 2024, analyzing contributions from various countries, institutions, authors, and journals, as well as key topics, keywords, and references. By incorporating cancer-type-specific thematic analysis, the study not only identifies global research patterns and hotspots but also delineates the translational progress and unmet clinical needs across major tumor types. The findings highlight current research hotspots and emerging trends, offering valuable insights for future advancements in the field.
- 4 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1553-1579
Open AccessWorldwide research on 3D printing for cancer: a dual-method analysis of bibliometrics and stratified focused thematic
Aim: This study investigates the application of three-dimensional (3D) printing in cancer research and treatment, highlighting the current advancements, key areas of interest, and emerging trends in the field. Methods: Literature records and cited references were retrieved from the Web of Science Core Collection (WOSCC) database and analyzed using Excel 2019, Bibliometrix, VOSviewer, and CiteSpace. Based on the scientometric results, a stratified and focused thematic analysis was performed by cancer type to enhance clinical relevance and investigate tumor-specific applications. Results: A total of 2312 publications on 3D printing in cancer were identified, with the earliest published in 2006. Publications originated from 2740 institutions across 82 countries, with China leading the field with 779 articles. Sichuan University was the most prolific institution, publishing 75 articles. Frontiers in Oncology had the highest number of publications with 49 publications, while Biomaterials was the most frequently cited journal with 3354 citations. Contributions to the field have been made by 13 066 contributing authors, with Tu Chongqi having 39 publications being the most productive. Key research areas focus on utilizing 3D printing for preoperative planning and patient education in tumor surgery, treating malignant bone tumors, advancing tumor radiotherapy, constructing in vitro tumor cell models, and expanding 3D bioprinting applications in cancer therapy. Future directions may include developments in limb-salvage and prosthetic reconstruction, the use of 3D bioprinting tumor microenvironment (TME) models to investigate antitumor mechanisms, and applications of 3D printing in cancer drug resistance. Among the most frequently studied tumor types, research on malignant bone tumors has primarily focused on reconstruction and tissue regeneration. In breast cancer, key areas include surgical planning, radiotherapy bolus design, tumor microenvironment modeling, and drug delivery. Lung cancer studies have emphasized surgical simulation, imaging phantoms, and bioprinted tumor models, while cervical cancer research has concentrated on customized brachytherapy applicators and preclinical bioprinting platforms. Additional insights on liver, prostate, head and neck, colorectal cancers, and glioblastoma are provided in the supplementary tables to support targeted research efforts. Conclusions: This study provides a comprehensive overview of the global applications of 3D printing in cancer research from 2000 to 2024, analyzing contributions from various countries, institutions, authors, and journals, as well as key topics, keywords, and references. By incorporating cancer-type-specific thematic analysis, the study not only identifies global research patterns and hotspots but also delineates the translational progress and unmet clinical needs across major tumor types. The findings highlight current research hotspots and emerging trends, offering valuable insights for future advancements in the field.
- Open Access
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1619607
Bone metastasis and pain research through the dual lens of bibliometrics and bioinformatics: knowledge structure, frontiers, and core pathway analysis (2015–2024)
Background: Cancer-induced bone pain (CIBP) represents a formidable clinical challenge with complex mechanisms, and existing treatments remain unable to effectively control pain in many patients. This study combined bibliometric and bioinformatic approaches to delineate key research trends, principal themes and future directions in the field of bone metastasis and pain research over the past decade (2015–2024).Methods: We selected 1,822 relevant documents from the Web of Science Core Collection for bibliometric analysis to identify major research characteristics, collaboration networks and emerging trends. Additionally, we employed bioinformatic methods to screen core genes associated with both bone metastasis and cancer pain, and analysed their functions and signalling pathways.Results: Research output and academic influence demonstrated an upward trajectory, with the United States and China being the countries with the highest publication volumes. Research hotspots are shifting from traditional palliative treatments towards precision therapies, with stereotactic body radiotherapy, minimally invasive ablation techniques and neuropathic pain mechanisms representing major research frontiers. Bioinformatic analysis identified core hub genes such as TP53 and EGFR, and revealed significant enrichment of signalling pathways including PI3K-Akt, MAPK and TNF in the common pathological processes of bone metastasis and pain.Conclusion: This study, for the first time combining both methodologies, revealed the field’s evolution from traditional treatments towards precision interventions and mechanistic exploration. The molecular targets and signalling pathways we identified provide promising directions for developing novel therapies capable of simultaneously controlling tumour progression and alleviating pain.
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1619607
Open AccessBone metastasis and pain research through the dual lens of bibliometrics and bioinformatics: knowledge structure, frontiers, and core pathway analysis (2015–2024)
Background: Cancer-induced bone pain (CIBP) represents a formidable clinical challenge with complex mechanisms, and existing treatments remain unable to effectively control pain in many patients. This study combined bibliometric and bioinformatic approaches to delineate key research trends, principal themes and future directions in the field of bone metastasis and pain research over the past decade (2015–2024).Methods: We selected 1,822 relevant documents from the Web of Science Core Collection for bibliometric analysis to identify major research characteristics, collaboration networks and emerging trends. Additionally, we employed bioinformatic methods to screen core genes associated with both bone metastasis and cancer pain, and analysed their functions and signalling pathways.Results: Research output and academic influence demonstrated an upward trajectory, with the United States and China being the countries with the highest publication volumes. Research hotspots are shifting from traditional palliative treatments towards precision therapies, with stereotactic body radiotherapy, minimally invasive ablation techniques and neuropathic pain mechanisms representing major research frontiers. Bioinformatic analysis identified core hub genes such as TP53 and EGFR, and revealed significant enrichment of signalling pathways including PI3K-Akt, MAPK and TNF in the common pathological processes of bone metastasis and pain.Conclusion: This study, for the first time combining both methodologies, revealed the field’s evolution from traditional treatments towards precision interventions and mechanistic exploration. The molecular targets and signalling pathways we identified provide promising directions for developing novel therapies capable of simultaneously controlling tumour progression and alleviating pain.